Global Blood Therapeutics Stock Price Target

December 04, 2020 Post a Comment

3995 Spread Highest target. Global Blood Therapeutics NASDAQGBT had its price objective decreased by Cantor Fitzgerald from 12000 to 11000 in a research note released on Friday morning The Fly reports.

Will Global Blood Therapeutics Gbt Report Negative Q1 Earnings What You Should Know Nasdaq

Global Blood Therapeutics Inc NASDAQ.

Global blood therapeutics stock price target. 203 rows This price target is based on 19 analysts offering 12 month price targets for Global Blood. Global Blood Therapeutics NASDAQGBT had its target price lowered by equities researchers at Roth Capital from 12800 to 12400 in a research report issued to clients and investors on Wednesday Benzinga reports. Zacks Investment Research upgraded Global Blood Therapeutics from a sell rating.

11 rows Target Lowered by. Average Target Price. Based on 14 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months.

The firm currently has a buy rating on the stock. Several other equities research analysts also recently commented on the company. Wolfe Research initiated coverage on shares of Global Blood Therapeutics in a research note on Wednesday March 17th.

1 day agoGiven Global Blood Therapeutics higher probable upside analysts clearly believe Global Blood Therapeutics is more favorable than Xenetic Biosciences. The average price target represents a 11852 increase from the last price of 3779. 13300 The average price target includes all analyst analysis not just the most recent analysis presented in the chart.

Global Blood Therapeutics has a beta of 139 meaning that its stock price is 39 more volatile than the SP 500. The company offers Oxbryta tablets an oral once-daily therapy for sickle cell disease SCD. The average price target is 8258 with a high forecast of 13800 and a low forecast of 4000.

Global Blood Therapeutics NASDAQGBT Price Target and Consensus Rating 18 Wall Street analysts have issued ratings and price targets for Global Blood Therapeutics in the last 12 months. 8 Wall Street analysts that have issued a 1 year GBT price target the average GBT price target is 7688 with the highest GBT stock price forecast at 12900 and the lowest GBT stock price forecast at 4500. Detailed list of analyst forecasts.

Cantor Fitzgeralds target price points to a potential upside of 18773 from the companys previous close. 31 2020 at 804 am. 8070 Last Close Price.

Average target price. They currently have a hold rating on the stock. Amount of Analyst Coverage Global Blood Therapeutics has been the subject of 6 research reports in the past 90 days demonstrating strong analyst interest in this stock.

Spread Lowest Target. Their average twelve-month price target is 8512 predicting that the stock has a. Q1 sales of 3904 million well below the consensus of 4300 million al.

According to analysts consensus price target of 8512 Global Blood Therapeutics has a forecasted upside of 1272 from its current price of 3747. ET by Tomi Kilgore. Find the latest Global Blood Therapeutics Inc.

GBT reported a Q1 EPS loss of 121 wider than the anticipated loss estimate of 101. Global Blood Therapeutics stock price target cut to 75 from 110 at SunTrust RH. They issued an outperform.

Spread Average Target. GBT stock quote history news and other vital information to help you with your stock trading and investing. Global Blood Therapeutics NASDAQGBT had its target price cut by analysts at Cantor Fitzgerald from 12000 to 11000 in a report released on Friday The Fly reports.

Price Price Target Lowest. Global Blood Therapeutics NASDAQGBT had its target price reduced by Canaccord Genuity from 4500 to 4000 in a report issued on Wednesday Benzinga reports. The brokerage presently has an overweight rating on the stock.

Global Blood Therapeutics Inc a biopharmaceutical company engages in the discovery development and delivery of treatments for underserved patient communities. Cantor Fitzgerald currently has an overweight rating on the stock.

Ihkjqojraugqmm